Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PEGging Krystexxa

Following a positive panel review in June, Savient Pharmaceuticals Inc. expected to spend the week leading up to its Aug. 1 PDUFA date finalizing the launch of its Krystexxa pegloticase for chronic refractory gout candidate. Instead, the biotech will have to spend the next three to six months revalidating its manufacturing process after receiving a complete response letter from FDA.

Krystexxa is a tetramer composed of four urate oxidase (uricase) monomers, with strands of PEG attached to specific spots on each monomer.

Manufacturing for the

Read the full 834 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE